List view / Grid view

Nature

 

article

An IgM antibody platform to tackle SARS-CoV-2 and its variants

23 September 2021 | By

Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…